JP2005519634A - 核酸組成物及びアレイ及びそれらを用いる方法 - Google Patents
核酸組成物及びアレイ及びそれらを用いる方法 Download PDFInfo
- Publication number
- JP2005519634A JP2005519634A JP2003587960A JP2003587960A JP2005519634A JP 2005519634 A JP2005519634 A JP 2005519634A JP 2003587960 A JP2003587960 A JP 2003587960A JP 2003587960 A JP2003587960 A JP 2003587960A JP 2005519634 A JP2005519634 A JP 2005519634A
- Authority
- JP
- Japan
- Prior art keywords
- chromosome
- nucleic acid
- syndrome
- locus
- detected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 752
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 449
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 449
- 238000000034 method Methods 0.000 title claims abstract description 209
- 238000003491 array Methods 0.000 title abstract description 62
- 239000000203 mixture Substances 0.000 title description 12
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 576
- 230000002759 chromosomal effect Effects 0.000 claims abstract description 87
- 208000031404 Chromosome Aberrations Diseases 0.000 claims abstract description 86
- 230000005861 gene abnormality Effects 0.000 claims abstract description 66
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims abstract description 59
- 238000012217 deletion Methods 0.000 claims abstract description 41
- 230000037430 deletion Effects 0.000 claims abstract description 41
- 238000003745 diagnosis Methods 0.000 claims abstract description 19
- 208000036878 aneuploidy Diseases 0.000 claims abstract description 17
- 231100001075 aneuploidy Toxicity 0.000 claims abstract description 17
- 210000000349 chromosome Anatomy 0.000 claims description 901
- 238000009396 hybridization Methods 0.000 claims description 107
- 238000001514 detection method Methods 0.000 claims description 100
- 239000012634 fragment Substances 0.000 claims description 98
- 108020004414 DNA Proteins 0.000 claims description 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 66
- 201000010099 disease Diseases 0.000 claims description 60
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 40
- 239000000758 substrate Substances 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 36
- 230000005856 abnormality Effects 0.000 claims description 33
- 210000001766 X chromosome Anatomy 0.000 claims description 32
- 210000002593 Y chromosome Anatomy 0.000 claims description 26
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 26
- 238000002372 labelling Methods 0.000 claims description 25
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 24
- 238000005406 washing Methods 0.000 claims description 24
- 210000004507 artificial chromosome Anatomy 0.000 claims description 23
- 201000009009 Charcot-Marie-Tooth disease type 1A Diseases 0.000 claims description 22
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 22
- 230000002068 genetic effect Effects 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 19
- 239000000975 dye Substances 0.000 claims description 19
- 201000003702 glycerol kinase deficiency Diseases 0.000 claims description 19
- 208000026203 inborn glycerol kinase deficiency Diseases 0.000 claims description 19
- 230000003252 repetitive effect Effects 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 17
- 208000006254 Wolf-Hirschhorn Syndrome Diseases 0.000 claims description 16
- 239000007850 fluorescent dye Substances 0.000 claims description 16
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 201000000866 velocardiofacial syndrome Diseases 0.000 claims description 16
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 15
- 210000001106 artificial yeast chromosome Anatomy 0.000 claims description 15
- 230000000295 complement effect Effects 0.000 claims description 14
- 201000001119 neuropathy Diseases 0.000 claims description 14
- 230000007823 neuropathy Effects 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 210000004209 hair Anatomy 0.000 claims description 13
- 208000026079 recessive X-linked ichthyosis Diseases 0.000 claims description 13
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims description 12
- 208000009575 Angelman syndrome Diseases 0.000 claims description 12
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims description 12
- 206010049644 Williams syndrome Diseases 0.000 claims description 12
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 11
- 208000001001 X-linked ichthyosis Diseases 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 210000000688 human artificial chromosome Anatomy 0.000 claims description 11
- 238000003499 nucleic acid array Methods 0.000 claims description 11
- 208000005801 spondylosis Diseases 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 10
- 208000034079 Monosomy 9p Diseases 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 208000006720 Potocki-Shaffer syndrome Diseases 0.000 claims description 10
- 201000007960 WAGR syndrome Diseases 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 201000001329 chromosome 9p deletion syndrome Diseases 0.000 claims description 10
- 230000000052 comparative effect Effects 0.000 claims description 10
- 238000013519 translation Methods 0.000 claims description 10
- 208000020570 3p deletion syndrome Diseases 0.000 claims description 9
- 208000003449 Classical Lissencephalies and Subcortical Band Heterotopias Diseases 0.000 claims description 9
- 206010010539 Congenital megacolon Diseases 0.000 claims description 9
- 208000004592 Hirschsprung disease Diseases 0.000 claims description 9
- 201000004246 Miller-Dieker lissencephaly syndrome Diseases 0.000 claims description 9
- 208000035022 Miller-Dieker syndrome Diseases 0.000 claims description 9
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 claims description 9
- 206010033799 Paralysis Diseases 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 9
- -1 chloromethyl phenyl moiety Chemical group 0.000 claims description 9
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 9
- 208000034076 BOR syndrome Diseases 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 210000001136 chorion Anatomy 0.000 claims description 8
- 230000002860 competitive effect Effects 0.000 claims description 8
- 238000000799 fluorescence microscopy Methods 0.000 claims description 8
- 239000013642 negative control Substances 0.000 claims description 8
- 239000013641 positive control Substances 0.000 claims description 8
- 230000002441 reversible effect Effects 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 208000004780 Potocki-Lupski syndrome Diseases 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 7
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical group [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 7
- 206010008748 Chorea Diseases 0.000 claims description 6
- 206010011385 Cri-du-chat syndrome Diseases 0.000 claims description 6
- 206010071437 Dyschondrosteosis Diseases 0.000 claims description 6
- 201000001934 Leri-Weill dyschondrosteosis Diseases 0.000 claims description 6
- 208000001804 Monosomy 5p Diseases 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 206010071135 branchio-oto-renal syndrome Diseases 0.000 claims description 6
- 208000013667 paroxysmal dyskinesia Diseases 0.000 claims description 6
- 241000702191 Escherichia virus P1 Species 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 5
- 208000021090 palsy Diseases 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 210000004381 amniotic fluid Anatomy 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 238000004590 computer program Methods 0.000 claims description 4
- 239000013601 cosmid vector Substances 0.000 claims description 4
- 150000004292 cyclic ethers Chemical class 0.000 claims description 4
- 210000002308 embryonic cell Anatomy 0.000 claims description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 208000016361 genetic disease Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 201000001388 Smith-Magenis syndrome Diseases 0.000 claims 5
- 230000006835 compression Effects 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 230000003321 amplification Effects 0.000 abstract description 24
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 24
- 238000004393 prognosis Methods 0.000 abstract description 12
- 239000000523 sample Substances 0.000 description 147
- 239000000047 product Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 21
- 201000006347 Intellectual Disability Diseases 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 101000603323 Homo sapiens Nuclear receptor subfamily 0 group B member 1 Proteins 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 230000003595 spectral effect Effects 0.000 description 11
- 208000034431 Adrenal hypoplasia congenita Diseases 0.000 description 10
- 208000005875 Alternating hemiplegia of childhood Diseases 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 206010058314 Dysplasia Diseases 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000013615 primer Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000001815 facial effect Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 230000005945 translocation Effects 0.000 description 8
- 238000000018 DNA microarray Methods 0.000 description 7
- 101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 description 7
- 102100035917 Peripheral myelin protein 22 Human genes 0.000 description 7
- 230000009395 genetic defect Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 102100023903 Glycerol kinase Human genes 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000013074 reference sample Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 208000033929 Birt-Hogg-Dubé syndrome Diseases 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000000723 mammalian artificial chromosome Anatomy 0.000 description 5
- 208000004141 microcephaly Diseases 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002559 cytogenic effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003917 human chromosome Anatomy 0.000 description 4
- 206010021198 ichthyosis Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000010453 quartz Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 201000006892 Charcot-Marie-Tooth disease type 1 Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100037260 Gap junction beta-1 protein Human genes 0.000 description 3
- 206010058359 Hypogonadism Diseases 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101150063042 NR0B1 gene Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 208000037280 Trisomy Diseases 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 208000037824 growth disorder Diseases 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 230000008775 paternal effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 208000018311 Autosomal trisomy Diseases 0.000 description 2
- 208000017843 C syndrome Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000005917 Exostoses Diseases 0.000 description 2
- 101000601647 Homo sapiens Paired box protein Pax-6 Proteins 0.000 description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 201000008645 Joubert syndrome Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- 206010028182 Multiple congenital abnormalities Diseases 0.000 description 2
- 208000025634 Multiple congenital anomalies/dysmorphic syndrome-intellectual disability Diseases 0.000 description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 2
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102100037506 Paired box protein Pax-6 Human genes 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000020584 Polyploidy Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010037213 Psychomotor retardation Diseases 0.000 description 2
- 108010066717 Q beta Replicase Proteins 0.000 description 2
- 208000033712 Self injurious behaviour Diseases 0.000 description 2
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 2
- 102100038021 Steryl-sulfatase Human genes 0.000 description 2
- 102000005262 Sulfatase Human genes 0.000 description 2
- 208000035167 Xp21 deletion syndrome Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 208000025261 autosomal dominant disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000701 chemical imaging Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 108010015416 connexin 32 Proteins 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 201000010934 exostosis Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000005350 fused silica glass Substances 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- 208000030454 monosomy Diseases 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108060007951 sulfatase Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 206010053884 trisomy 18 Diseases 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical class CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- PGZBPTIIKILSER-UHFFFAOYSA-N 1-(2H-isoindol-1-yl)-3-methylideneisoindole Chemical class C=1(NC=C2C=CC=CC12)C1=NC(C2=CC=CC=C12)=C PGZBPTIIKILSER-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical class CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 201000011374 Alagille syndrome Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000370419 Brachycephalus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 208000000380 Cafe-au-Lait Spots Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 201000008993 Charcot-Marie-Tooth disease type 1C Diseases 0.000 description 1
- 206010008754 Choreoathetosis Diseases 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000031639 Chromosome Deletion Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000008020 Cohen syndrome Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 208000004468 Craniofacial Abnormalities Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000035976 Developmental Disabilities Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 208000001692 Esotropia Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150116966 Ext1 gene Proteins 0.000 description 1
- 208000023281 Fallot tetralogy Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100477520 Homo sapiens SHOX gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 206010064024 Intestinal malrotation Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000029301 Mastication disease Diseases 0.000 description 1
- 208000033334 Maternal uniparental disomy Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027543 Micrognathia Diseases 0.000 description 1
- 208000002598 Micrognathism Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 101150082519 PLP1 gene Proteins 0.000 description 1
- 101150038744 PMP22 gene Proteins 0.000 description 1
- 208000010633 Partial duplication of the short arm of chromosome 3 Diseases 0.000 description 1
- 201000009928 Patau syndrome Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 206010052649 Primary hypogonadism Diseases 0.000 description 1
- 208000008708 Prognathism Diseases 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 208000033787 Rare developmental defect during embryogenesis Diseases 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101150059736 SRY gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004487 Satellite DNA Proteins 0.000 description 1
- 206010039740 Screaming Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 108700025071 Short Stature Homeobox Proteins 0.000 description 1
- 102100029992 Short stature homeobox protein Human genes 0.000 description 1
- 239000004965 Silica aerogel Substances 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 201000003005 Tetralogy of Fallot Diseases 0.000 description 1
- 206010044686 Trisomy 13 Diseases 0.000 description 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 208000031655 Uniparental Disomy Diseases 0.000 description 1
- 101150046474 Vhl gene Proteins 0.000 description 1
- OYVGFASYJHUBSP-YGOYTEALSA-N [[(2r,3s,5r)-5-(4,5-diamino-2-oxopyrimidin-1-yl)-3-hydroxy-5-prop-2-ynyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(N)=CN1[C@]1(CC#C)O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 OYVGFASYJHUBSP-YGOYTEALSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 208000008303 aniridia Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 201000006715 brachydactyly Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000001444 catalytic combustion detection Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 208000005093 cerebellar hypoplasia Diseases 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 208000022734 developmental defect during embryogenesis Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- OKZIUSOJQLYFSE-UHFFFAOYSA-N difluoroboron Chemical compound F[B]F OKZIUSOJQLYFSE-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000027110 duplication/inversion 15q11 Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000005831 heart abnormality Effects 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000055071 human NR0B1 Human genes 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000006237 infantile hypercalcemia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000000050 ionisation spectroscopy Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005830 kidney abnormality Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000032646 lung growth Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000035853 malformation syndrome Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000236 metacarpal bone Anatomy 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007902 molecular cytogenetic technique Methods 0.000 description 1
- XTGGILXPEMRCFM-UHFFFAOYSA-N morpholin-4-yl carbamate Chemical compound NC(=O)ON1CCOCC1 XTGGILXPEMRCFM-UHFFFAOYSA-N 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008859 olfactory neuroblastoma Diseases 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000016685 primary ovarian failure Diseases 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 208000028103 tetrasomy 9p Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- OVTCUIZCVUGJHS-VQHVLOKHSA-N trans-dipyrrin Chemical compound C=1C=CNC=1/C=C1\C=CC=N1 OVTCUIZCVUGJHS-VQHVLOKHSA-N 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000027617 trisomy 5p Diseases 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 208000007210 volvulus of midgut Diseases 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B20/00—Methods specially adapted for identifying library members
- C40B20/04—Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
- C40B60/10—Apparatus specially adapted for use in combinatorial chemistry or with libraries for identifying library members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32903001P | 2001-10-12 | 2001-10-12 | |
| PCT/US2002/033044 WO2003091426A1 (en) | 2001-10-12 | 2002-10-15 | Compilations of nucleic acids and arrays and methods of using them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519634A true JP2005519634A (ja) | 2005-07-07 |
| JP2005519634A5 JP2005519634A5 (https=) | 2006-01-05 |
Family
ID=29270419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587960A Pending JP2005519634A (ja) | 2001-10-12 | 2002-10-15 | 核酸組成物及びアレイ及びそれらを用いる方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7335470B2 (https=) |
| EP (1) | EP1451318A4 (https=) |
| JP (1) | JP2005519634A (https=) |
| AU (1) | AU2002367886B8 (https=) |
| CA (1) | CA2463725A1 (https=) |
| WO (1) | WO2003091426A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2011049237A1 (ja) * | 2009-10-23 | 2013-03-14 | 公益財団法人東京都医学総合研究所 | 減感作療法における治療効果を予測するバイオマーカー |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0878552A1 (en) * | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
| US6979728B2 (en) * | 1998-05-04 | 2005-12-27 | Baylor College Of Medicine | Articles of manufacture and methods for array based analysis of biological molecules |
| JP2002513587A (ja) | 1998-05-04 | 2002-05-14 | ダコ エー エス | 染色体異常を検出するための方法およびプローブ |
| US20050032060A1 (en) * | 2001-08-31 | 2005-02-10 | Shishir Shah | Arrays comprising pre-labeled biological molecules and methods for making and using these arrays |
| US7439346B2 (en) | 2001-10-12 | 2008-10-21 | Perkinelmer Las Inc. | Nucleic acids arrays and methods of use therefor |
| CA2463725A1 (en) | 2001-10-12 | 2003-11-06 | Spectral Genomics, Inc. | Compilations of nucleic acids and arrays and methods of using them |
| US20090075841A1 (en) * | 2002-10-15 | 2009-03-19 | Johnson Robert C | Nucleic acids arrays and methods of use therefor |
| US8232055B2 (en) * | 2002-12-23 | 2012-07-31 | Agilent Technologies, Inc. | Comparative genomic hybridization assays using immobilized oligonucleotide features and compositions for practicing the same |
| CA2545917C (en) * | 2003-11-14 | 2014-07-29 | Duke University | Methods of detecting charcot-marie tooth disease type 2a |
| US8321138B2 (en) * | 2005-07-29 | 2012-11-27 | Agilent Technologies, Inc. | Method of characterizing quality of hybridized CGH arrays |
| US20070031883A1 (en) * | 2004-03-04 | 2007-02-08 | Kincaid Robert H | Analyzing CGH data to identify aberrations |
| EP1766061B1 (en) * | 2004-05-20 | 2013-07-17 | Quest Diagnostics Investments Incorporated | Single label comparative hybridization |
| EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| NZ554824A (en) | 2004-10-22 | 2010-10-29 | Revivicor Inc | Porcines that lack endogenous antibody chains and express exogenous immunoglobulins |
| CA2857881A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| US20070072175A1 (en) * | 2005-05-13 | 2007-03-29 | Biogen Idec Ma Inc. | Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof |
| US8076074B2 (en) * | 2005-11-29 | 2011-12-13 | Quest Diagnostics Investments Incorporated | Balanced translocation in comparative hybridization |
| WO2007095007A2 (en) * | 2006-02-14 | 2007-08-23 | Albert Einstein College Of Medicine Of Yeshiva University | Systematic genomic library and uses thereof |
| WO2008030065A1 (en) * | 2006-09-08 | 2008-03-13 | Macrogen Inc. | Microarray chip and method for detection of chromosomal abnormality |
| WO2008036765A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| JP2010510964A (ja) | 2006-09-19 | 2010-04-08 | アシュラジェン インコーポレイテッド | 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路 |
| US20080102453A1 (en) * | 2006-10-31 | 2008-05-01 | Jayati Ghosh | Methods and systems and analysis of CGH data |
| US7507539B2 (en) * | 2007-07-30 | 2009-03-24 | Quest Diagnostics Investments Incorporated | Substractive single label comparative hybridization |
| US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
| US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
| US20100159506A1 (en) * | 2008-07-25 | 2010-06-24 | Cellscape Corporation | Methods and systems for genetic analysis of fetal nucleated red blood cells |
| JP5331404B2 (ja) * | 2008-08-01 | 2013-10-30 | 国立大学法人 東京医科歯科大学 | 先天性異常症の染色体欠失の検出方法 |
| RU2546291C2 (ru) * | 2008-08-14 | 2015-04-10 | Нестек С.А. | Композиции и способы воздействия на насыщение, липидный метаболизм и потребление жира |
| EP2348827B1 (en) | 2008-10-27 | 2015-07-01 | Revivicor, Inc. | Immunocompromised ungulates |
| WO2011067234A2 (en) * | 2009-12-02 | 2011-06-09 | Roche Diagnostics Gmbh | Multiplexed microarray and method of fabricating thereof |
| ES2631458T3 (es) | 2010-03-04 | 2017-08-31 | Interna Technologies B.V. | Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT |
| US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
| NZ704322A (en) | 2010-07-06 | 2016-07-29 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| US9803236B2 (en) * | 2010-08-06 | 2017-10-31 | Tsinghua University | Microarray-based assay integrated with particles for analyzing molecular interactions |
| EP2772550B1 (en) | 2010-11-17 | 2017-03-29 | Interpace Diagnostics, LLC | Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms |
| CA2819378A1 (en) | 2010-12-02 | 2012-06-07 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Irak-related interventions and diagnosis |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| EP2681566A2 (en) | 2011-02-28 | 2014-01-08 | University of Iowa Research Foundation | Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender |
| US8753873B2 (en) | 2011-04-15 | 2014-06-17 | Roche Nimblegen, Inc. | Multiplexed microarray assembly and method for fabricating a multiplexed microarray |
| WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
| WO2013063519A1 (en) | 2011-10-26 | 2013-05-02 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
| WO2013063544A1 (en) | 2011-10-27 | 2013-05-02 | Asuragen, Inc. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
| EP2870263A1 (en) | 2012-07-03 | 2015-05-13 | InteRNA Technologies B.V. | Diagnostic portfolio and its uses |
| WO2014055117A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
| EP2971132B1 (en) | 2013-03-15 | 2020-05-06 | Baylor Research Institute | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
| WO2014144666A2 (en) | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
| EP2971149B1 (en) | 2013-03-15 | 2018-05-09 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
| ES2421207B1 (es) * | 2013-05-31 | 2014-04-15 | Universidad De León | Procedimiento y kit de diagnóstico de lisencefalia con hipoplasia cerebelar en ganado ovino |
| DK3110973T3 (da) | 2014-02-27 | 2019-05-13 | Univ Leuven Kath | Oxidativt stress og kardiovaskulære sygdomshændelser |
| US10704097B2 (en) | 2014-02-27 | 2020-07-07 | Katholieke Universiteit Leuven | Oxidative stress and cardiovascular disease events |
| USRE50172E1 (en) | 2014-12-19 | 2024-10-15 | Vrije Universiteit Brussel | In vitro maturation of a mammalian cumulus oocyte complex |
| US11497762B2 (en) | 2017-11-03 | 2022-11-15 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| EP3714053B1 (en) | 2017-11-22 | 2025-12-31 | The University of Chicago | CHEMICALLY DEPENDENT PROBE EVALUATION OF PROTEIN ACTIVITY AND ITS USES |
| CN114174532A (zh) | 2019-04-05 | 2022-03-11 | 德克萨斯大学系统董事会 | 细胞条形码编码的方法和应用 |
| WO2020210521A2 (en) | 2019-04-12 | 2020-10-15 | The Regents Of The University Of California | Compositions and methods for increasing muscle mass and oxidative metabolism |
| WO2022120196A2 (en) * | 2020-12-03 | 2022-06-09 | Cytotest Inc. | Nucleic acid probes |
| WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
| WO2025248505A1 (en) | 2024-05-31 | 2025-12-04 | Wayne State University | Methods for treating endometrial and ovarian hyperproliferative disorders |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998055593A1 (en) * | 1997-06-06 | 1998-12-10 | Orchid Biocomputer, Inc. | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
| JPH11510681A (ja) * | 1994-12-09 | 1999-09-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 核酸アレイへの比較蛍光ハイブリダイゼーション |
| JP2000232883A (ja) * | 1999-02-02 | 2000-08-29 | Vysis Inc | 核酸ミクロアレイを用いる遺伝子発現およびゲノム異常の同時測定 |
| EP1132739A1 (en) * | 2000-05-16 | 2001-09-12 | BioChip Technologies GmbH | Linker system for activating surfaces for bioconjugation and methods for their use |
| JP2003021635A (ja) * | 2001-07-06 | 2003-01-24 | Dainippon Printing Co Ltd | マイクロアレイチップ |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55116259A (en) | 1979-03-01 | 1980-09-06 | Fuji Photo Film Co Ltd | Microimmunoassay method |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0047472B1 (en) | 1980-09-02 | 1985-04-24 | Fuji Photo Film Co., Ltd. | Method for immunochemical measurement of trace components |
| US4355153A (en) | 1980-11-19 | 1982-10-19 | Societa' Italiana Resine S.I.R. S.P.A. | Process for the polymerization of formaldehyde |
| CA1253129A (en) * | 1984-02-09 | 1989-04-25 | Thomas R. Jones | Porous inorganic materials |
| US4957858A (en) * | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| US4818681A (en) * | 1985-02-22 | 1989-04-04 | Molecular Diagnostics, Inc. | Fast and specific immobilization of nucleic acids to solid supports |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5641630A (en) * | 1985-06-13 | 1997-06-24 | Amgen Inc. | Method and kit for performing nucleic acid hybridization assays |
| US4806631A (en) * | 1985-09-30 | 1989-02-21 | Miles Inc. | Immobilization of nucleic acids on solvolyzed nylon supports |
| US4652613A (en) | 1985-12-16 | 1987-03-24 | Celanese Corporation | Novel elastomer/oxymethylene polymer blends containing polymeric compatibilizing agents |
| US5721098A (en) | 1986-01-16 | 1998-02-24 | The Regents Of The University Of California | Comparative genomic hybridization |
| US5190864A (en) * | 1986-04-15 | 1993-03-02 | Northeastern University | Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material |
| US4937188A (en) * | 1986-04-15 | 1990-06-26 | Northeastern University | Enzyme activity amplification method for increasing assay sensitivity |
| US6048982A (en) | 1986-04-18 | 2000-04-11 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
| US5268486A (en) | 1986-04-18 | 1993-12-07 | Carnegie-Mellon Unversity | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
| US5047519A (en) | 1986-07-02 | 1991-09-10 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
| US5151507A (en) | 1986-07-02 | 1992-09-29 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
| US5135717A (en) | 1986-12-24 | 1992-08-04 | British Technology Group Usa Inc. | Tetrabenztriazaporphyrin reagents and kits containing the same |
| US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
| US5055429A (en) * | 1987-11-27 | 1991-10-08 | Ecc International Limited | Porous inorganic material |
| GB8803413D0 (en) * | 1988-02-15 | 1988-03-16 | Ecc Int Ltd | Biological support |
| US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5024933A (en) * | 1988-05-10 | 1991-06-18 | Enzo Biochem, Inc. | Method and kit for sample adherence to test substrate |
| US5602244A (en) | 1988-05-26 | 1997-02-11 | Competitive Technologies, Inc. | Polynucleotide phosphorodithioate compounds |
| WO1990009441A1 (en) | 1989-02-01 | 1990-08-23 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
| US5925525A (en) * | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6309822B1 (en) * | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
| US6416952B1 (en) * | 1989-06-07 | 2002-07-09 | Affymetrix, Inc. | Photolithographic and other means for manufacturing arrays |
| US6040138A (en) * | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| DE3929150A1 (de) | 1989-09-02 | 1991-03-07 | Akzo Gmbh | Cellulosische membranen |
| US5188934A (en) | 1989-11-14 | 1993-02-23 | Applied Biosystems, Inc. | 4,7-dichlorofluorescein dyes as molecular probes |
| US5215882A (en) * | 1989-11-30 | 1993-06-01 | Ortho Diagnostic Systems, Inc. | Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays |
| FR2659349B1 (fr) | 1990-03-12 | 1993-12-24 | Rhone Merieux | Virus herpes recombinants notamment pour la realisation de vaccins, leur procede de preparation, les plasmides realises au cours de ce procede et les vaccins obtenus. |
| US5227487A (en) | 1990-04-16 | 1993-07-13 | Molecular Probes, Inc. | Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes |
| US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
| US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
| ES2116977T3 (es) * | 1990-05-11 | 1998-08-01 | Microprobe Corp | Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente. |
| US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
| US5817462A (en) | 1995-02-21 | 1998-10-06 | Applied Spectral Imaging | Method for simultaneous detection of multiple fluorophores for in situ hybridization and multicolor chromosome painting and banding |
| US5936731A (en) | 1991-02-22 | 1999-08-10 | Applied Spectral Imaging Ltd. | Method for simultaneous detection of multiple fluorophores for in situ hybridization and chromosome painting |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| US5300687A (en) | 1991-07-18 | 1994-04-05 | Ortho Pharmaceutical Corporation | Trifluoromethylbenzylphosphonates useful in treating osteoporosis |
| US5288625A (en) | 1991-09-13 | 1994-02-22 | Biologic Research Center Of The Hungarian Academy Of Sciences | Mammalian artificial chromosomes |
| US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
| US5846708A (en) | 1991-11-19 | 1998-12-08 | Massachusetts Institiute Of Technology | Optical and electrical methods and apparatus for molecule detection |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5652099A (en) | 1992-02-12 | 1997-07-29 | Conrad; Michael J. | Probes comprising fluorescent nucleosides and uses thereof |
| JPH05236997A (ja) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | ポリヌクレオチド捕捉用チップ |
| US5965362A (en) * | 1992-03-04 | 1999-10-12 | The Regents Of The University Of California | Comparative genomic hybridization (CGH) |
| ATE205542T1 (de) * | 1992-03-04 | 2001-09-15 | Univ California | Vergleichende genomhybridisierung |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| EP0767361B1 (en) | 1993-07-22 | 2000-02-23 | Applied Spectral Imaging Ltd. | Method and apparatus for spectral imaging |
| WO1995003400A1 (en) | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
| US6001982A (en) | 1993-07-29 | 1999-12-14 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| US5637687A (en) * | 1993-08-31 | 1997-06-10 | Wiggins; James C. | Methods and compositions for isolating nucleic acids |
| US5472842A (en) * | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| ATE424927T1 (de) | 1993-10-28 | 2009-03-15 | Houston Advanced Res Ct | Mikrofabriziertes poröses durchflussgerät zur diskreten bestimmung von bindungsreaktionen |
| US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
| US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
| US5610287A (en) * | 1993-12-06 | 1997-03-11 | Molecular Tool, Inc. | Method for immobilizing nucleic acid molecules |
| DE4344726C2 (de) | 1993-12-27 | 1997-09-25 | Deutsches Krebsforsch | Verfahren zum Nachweis von nicht balanciertem genetischen Material einer Spezies oder zum Nachweis der Genexpression in Zellen einer Spezies |
| US6028190A (en) | 1994-02-01 | 2000-02-22 | The Regents Of The University Of California | Probes labeled with energy transfer coupled dyes |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| EP0695941B1 (en) | 1994-06-08 | 2002-07-31 | Affymetrix, Inc. | Method and apparatus for packaging a chip |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5554744A (en) * | 1994-09-23 | 1996-09-10 | Hybridon, Inc. | Method for loading solid supports for nucleic acid synthesis |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5601982A (en) * | 1995-02-07 | 1997-02-11 | Sargent; Jeannine P. | Method and apparatus for determining the sequence of polynucleotides |
| US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
| US5635351A (en) | 1995-03-14 | 1997-06-03 | The Regents Of The University Of California | Genetic gain and loss in gliomas |
| US5863504A (en) | 1995-03-16 | 1999-01-26 | Bio-Rad Laboratories, Inc. | Fluorescence imaging instrument utilizing fish |
| US5962674A (en) | 1995-06-01 | 1999-10-05 | Hybridon, Inc. | Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages |
| CA2223103A1 (en) | 1995-06-06 | 1996-12-12 | Isis Pharmaceuticals Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5614386A (en) | 1995-06-23 | 1997-03-25 | Baylor College Of Medicine | Alternative dye-labeled primers for automated DNA sequencing |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| FR2736342B1 (fr) | 1995-07-07 | 1999-01-29 | Univ Claude Bernard Lyon | Procede pour la fabrication d'aerogels de silice monolithiques et aerogels de silice ainsi obtenus |
| US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| US5630932A (en) * | 1995-09-06 | 1997-05-20 | Molecular Imaging Corporation | Tip etching system and method for etching platinum-containing wire |
| US5734041A (en) | 1995-10-20 | 1998-03-31 | Mcgill University | Preparation of chiral phosphorothioate oligomers |
| US5721118A (en) | 1995-10-31 | 1998-02-24 | The Regents Of The University Of California, San Diego | Mammalian artificial chromosomes and methods of using same |
| AU714486B2 (en) | 1995-11-21 | 2000-01-06 | Yale University | Unimolecular segment amplification and detection |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| US5714386A (en) | 1996-01-11 | 1998-02-03 | Board Of Trustees Of The Leland Stanford Junior University | Cy7-allophycocyanin conjugates for use in multiplex fluorescence detection assays |
| EP0880598A4 (en) * | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US20010018514A1 (en) | 1998-07-31 | 2001-08-30 | Mcgall Glenn H. | Nucleic acid labeling compounds |
| US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
| US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| AU3568897A (en) | 1996-06-07 | 1998-01-05 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
| US5880473A (en) | 1997-07-28 | 1999-03-09 | Applied Imaging, Inc. | Multifluor-fluorescence in-situ hybridization (M-FISH) imaging techniques using multiple multiband filters with image registration |
| US6027709A (en) | 1997-01-10 | 2000-02-22 | Li-Cor Inc. | Fluorescent cyanine dyes |
| US5790727A (en) | 1997-02-05 | 1998-08-04 | Brookhaven Science Associates Llc | Laser illumination of multiple capillaries that form a waveguide |
| JPH10227740A (ja) | 1997-02-18 | 1998-08-25 | Hitachi Ltd | 多色蛍光検出電気泳動分析装置 |
| US6048457A (en) | 1997-02-26 | 2000-04-11 | Millipore Corporation | Cast membrane structures for sample preparation |
| US5846726A (en) | 1997-05-13 | 1998-12-08 | Becton, Dickinson And Company | Detection of nucleic acids by fluorescence quenching |
| US6063338A (en) | 1997-06-02 | 2000-05-16 | Aurora Biosciences Corporation | Low background multi-well plates and platforms for spectroscopic measurements |
| US5939261A (en) | 1997-06-24 | 1999-08-17 | Sarnoff Corporation | Method for capturing a nucleic acid |
| US6096817A (en) | 1997-06-26 | 2000-08-01 | E. I. Du Pont De Nemours And Company | Mixtures of polyimides and elastomers |
| US5914039A (en) | 1997-07-01 | 1999-06-22 | Zenon Environmental Inc. | Filtration membrane with calcined α-alumina particles therein |
| US6826296B2 (en) | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
| US5943129A (en) | 1997-08-07 | 1999-08-24 | Cambridge Research & Instrumentation Inc. | Fluorescence imaging system |
| US6294331B1 (en) | 1997-08-08 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for assessing genetic and phenotypic markers by simultaneous multicolor visualization of chromogenic dyes using brightfield microscopy and spectral imaging |
| US6223127B1 (en) | 1997-08-15 | 2001-04-24 | Affymetrix, Inc. | Polymorphism detection utilizing clustering analysis |
| CN1273609A (zh) | 1997-08-15 | 2000-11-15 | 希斯克有限公司 | 检测或量化核酸物类的方法和组合物 |
| US6294327B1 (en) | 1997-09-08 | 2001-09-25 | Affymetrix, Inc. | Apparatus and method for detecting samples labeled with material having strong light scattering properties, using reflection mode light and diffuse scattering |
| CN1677076A (zh) | 1997-09-11 | 2005-10-05 | 生物风险公司 | 制备高密度阵列的方法 |
| US6465178B2 (en) | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
| US5922617A (en) | 1997-11-12 | 1999-07-13 | Functional Genetics, Inc. | Rapid screening assay methods and devices |
| US6060324A (en) | 1997-11-12 | 2000-05-09 | Phytochem Technologies, Inc. | Fluorometric assay composition for measurement of antioxidant activity |
| US6049380A (en) | 1997-11-12 | 2000-04-11 | Regents Of The University Of California | Single molecule identification using selected fluorescence characteristics |
| US5874259A (en) | 1997-11-21 | 1999-02-23 | Wisconsin Alumni Research Foundation | Conditionally amplifiable BAC vector |
| US5936087A (en) | 1997-11-25 | 1999-08-10 | The Perkin-Elmer Corporation | Dibenzorhodamine dyes |
| US6277621B1 (en) | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
| US6077673A (en) * | 1998-03-31 | 2000-06-20 | Clontech Laboratories, Inc. | Mouse arrays and kits comprising the same |
| AU3463699A (en) | 1998-04-03 | 1999-10-25 | Phylos, Inc. | Addressable protein arrays |
| US6183957B1 (en) | 1998-04-16 | 2001-02-06 | Institut Pasteur | Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria |
| US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
| SE514568C2 (sv) | 1998-05-18 | 2001-03-12 | Allgon Ab | Antennanordning omfattande matningsmedel och en handburen radiokommunikationsanordning för en sådan antennanordning |
| DE69935230T2 (de) | 1998-08-10 | 2007-12-20 | Genomic Solutions, Inc., Ann Arbor | Vorrichtung für thermische und flüssige zirkulation zur hybridierung von nukleinsäuren |
| US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
| WO2000026412A1 (en) | 1998-11-02 | 2000-05-11 | Kenneth Loren Beattie | Nucleic acid analysis using sequence-targeted tandem hybridization |
| US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
| US6235504B1 (en) | 1999-01-11 | 2001-05-22 | The Rockefeller University | Methods for identifying genomic equivalent markers and their use in quantitating cells and polynucleotide sequences therein |
| WO2000042222A2 (en) | 1999-01-15 | 2000-07-20 | Gene Logic Inc. | Immobilized nucleic acid hybridization reagent and method |
| AU2877000A (en) | 1999-02-10 | 2000-08-29 | University Of Maryland | Photo-induced nucleic acid hybridization |
| US6277581B1 (en) | 1999-03-01 | 2001-08-21 | Lankenau Medical Research Center | ODC allelic analysis method for assessing carcinogenic susceptibility |
| US6221653B1 (en) | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
| AU6203700A (en) | 1999-06-30 | 2001-01-31 | Iris Biotechnologies, Inc. | Hybridization of target dna with immobilized nucleic acid analogs |
| AU781570B2 (en) | 1999-07-23 | 2005-06-02 | Gen-Probe Incorporated | Polynucleotide amplification method |
| US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
| US6252664B1 (en) | 1999-10-15 | 2001-06-26 | Biocrystal Ltd. | Fluorescence filter cube for fluorescence detection and imaging |
| US6383749B2 (en) | 1999-12-02 | 2002-05-07 | Clontech Laboratories, Inc. | Methods of labeling nucleic acids for use in array based hybridization assays |
| EP1106603A3 (en) | 1999-12-06 | 2003-11-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
| US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| CA2463725A1 (en) | 2001-10-12 | 2003-11-06 | Spectral Genomics, Inc. | Compilations of nucleic acids and arrays and methods of using them |
-
2002
- 2002-10-15 CA CA002463725A patent/CA2463725A1/en not_active Abandoned
- 2002-10-15 WO PCT/US2002/033044 patent/WO2003091426A1/en not_active Ceased
- 2002-10-15 AU AU2002367886A patent/AU2002367886B8/en not_active Ceased
- 2002-10-15 EP EP02807317A patent/EP1451318A4/en not_active Withdrawn
- 2002-10-15 US US10/273,399 patent/US7335470B2/en not_active Expired - Fee Related
- 2002-10-15 JP JP2003587960A patent/JP2005519634A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11510681A (ja) * | 1994-12-09 | 1999-09-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 核酸アレイへの比較蛍光ハイブリダイゼーション |
| WO1998055593A1 (en) * | 1997-06-06 | 1998-12-10 | Orchid Biocomputer, Inc. | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
| JP2000232883A (ja) * | 1999-02-02 | 2000-08-29 | Vysis Inc | 核酸ミクロアレイを用いる遺伝子発現およびゲノム異常の同時測定 |
| EP1132739A1 (en) * | 2000-05-16 | 2001-09-12 | BioChip Technologies GmbH | Linker system for activating surfaces for bioconjugation and methods for their use |
| JP2003021635A (ja) * | 2001-07-06 | 2003-01-24 | Dainippon Printing Co Ltd | マイクロアレイチップ |
Non-Patent Citations (3)
| Title |
|---|
| JPN6009035889, Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓｅａｒｃｈ， １９９２， Ｖｏｌ．２０， Ｎｏ．７， ｐｐ．１６７９−１６８４ * |
| JPN6009035890, Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓｅａｒｃｈ， １９９６， Ｖｏｌ．２４， Ｎｏ．１５， ｐｐ．３０３１−３０３９ * |
| JPN6009035891, Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓｅａｒｃｈ， １９９４， Ｖｏｌ．２２， Ｎｏ．１１， ｐｐ．２１２１−２１２５ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2011049237A1 (ja) * | 2009-10-23 | 2013-03-14 | 公益財団法人東京都医学総合研究所 | 減感作療法における治療効果を予測するバイオマーカー |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2463725A1 (en) | 2003-11-06 |
| US20040009493A1 (en) | 2004-01-15 |
| US7335470B2 (en) | 2008-02-26 |
| EP1451318A4 (en) | 2007-06-27 |
| AU2002367886B8 (en) | 2008-08-14 |
| AU2002367886A1 (en) | 2003-11-10 |
| WO2003091426A1 (en) | 2003-11-06 |
| AU2002367886B2 (en) | 2008-02-28 |
| EP1451318A1 (en) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519634A (ja) | 核酸組成物及びアレイ及びそれらを用いる方法 | |
| US7439346B2 (en) | Nucleic acids arrays and methods of use therefor | |
| US11081209B2 (en) | Methods for genome assembly and haplotype phasing | |
| AU2002330141B2 (en) | Methods for detecting genetic mosaicisms using arrays | |
| JP2007515947A (ja) | 羊水中の無細胞胎児ｄｎａを使用する出生前診断 | |
| AU2002330141A1 (en) | Methods for detecting genetic mosaicisms using arrays | |
| Liehr | Cytogenetics and molecular cytogenetics | |
| KR20190020133A (ko) | 염색체에 대한 인-시츄 혼성화를 위한 dna 탐침 | |
| US20090075841A1 (en) | Nucleic acids arrays and methods of use therefor | |
| US8021888B2 (en) | Rapid comparative genomic hybridization using acoustic surface waves | |
| US20030124542A1 (en) | Methods for mapping the chromosomal loci of genes expressed by a cell | |
| US20250283156A1 (en) | Parallel multiple displacement amplification method | |
| WO2024196728A2 (en) | Nucleic acid probes for combined sequencing and spatial analysis | |
| Gallardo et al. | Application to Assisted Reproductive of Whole-Genome Treatment Technologies | |
| EP1664273A2 (en) | Arrays, methods and kits for preparation and use of syntenic genomic arrays for diagnostics and toxicology | |
| HK40000941A (en) | Rapid sequencing of short dna fragments using nanopore technology | |
| HK1223660B (zh) | 一种测序文库的构建方法及试剂盒和应用 | |
| WO2010101273A1 (ja) | 精神遅滞を伴う多発性奇形症候群の判別方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051017 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060802 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080909 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081128 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091019 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091026 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091215 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100121 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100511 |